ArticleScientific reports2025
Combined effects of restriction factors and transduction adjuvants on lentiviral vector gene transfer efficacy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Restriction factors include various cellular proteins that detect and impede viral infections. Among them, interferon-induced transmembrane (IFITM) and serine incorporator (SERINC) proteins interfere with the infectious cycle of HIV-1. Consequently, such restriction factors can also interfere with gene transfer efficacy when using recombinant lentiviral vectors derived from HIV-1, but these parameters remain incompletely understood. Here, using overexpressing human cell lines, we investigated the effects of IFITM and SERINC proteins on key parameters in the infectivity of lentiviral vectors, e.g. the nature of the vector envelope glycoprotein pseudotype and the use of transduction adjuvants. Vectors pseudotyped with glycoproteins from vesiculoviruses were mostly insensitive to the effects of restriction factors whereas those pseudotyped with glycoproteins of retroviral origin displayed contrasted responses. IFITM2 and IFITM3 very effectively restricted Syncytin1-pseudotyped vectors. Two transduction adjuvants, Vectofusin and cyclosporin H, counteracted these effects. Addition of either of these compounds led to reduced IFITM2 and IFITM3 protein levels. These results may rationalize the choice of pseudotypes as well as transduction conditions to use for gene transfer. Together, these parameters can strongly enhance the transduction efficacy, especially in target cells that naturally express IFITM proteins, including human hematopoietic cells that are of particular clinical interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.